Healthcare / Medical Care FacilitiesNasdaqGS
$6.67
-0.50 (-6.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $72.4M · quality 15.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
115.7%
↑Gross Margin
33.3%
↓Debt/Equity
6.62
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2026 · 7 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.43B · net income $225.0M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $2.43B | $2.43B | $2.43B | $2.02B | $1.90B | $1.79B | $1.50B | $1.38B |
| Net Income | $225.0M | $225.0M | $225.0M | $-10.9M | $-134.5M | $-662.0M | $-57.0M | $-76.5M |
| EBITDA | $267.0M | $267.0M | $269.4M | $187.4M | $39.2M | $-525.1M | $13.5M | $53.3M |
| EPS | 1.05 | 1.05 | — | -0.06 | -0.71 | -3.57 | — | — |
| Gross Margin | 33.3% | 33.3% | 33.3% | 31.4% | 31.4% | 30.9% | 30.4% | 30.3% |
| Operating Margin | 10.5% | 10.5% | 10.7% | 7.0% | 6.0% | 1.9% | -0.2% | 2.8% |
| Net Margin | 9.2% | 9.2% | 9.2% | -0.5% | -7.1% | -37.0% | -3.8% | -5.5% |
| Balance Sheet | ||||||||
| Debt/Equity | 6.62 | 6.62 | 7.76 | -12.30 | -11.76 | -358.17 | 4.39 | — |
| Current Ratio | — | — | 1.47 | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | — | — | $118.4M | $26.3M | $13.9M | $-60.4M | $101.4M | $-25.4M |
| Returns | ||||||||
| ROE | 115.7% | 115.7% | 115.3% | 9.0% | 105.6% | 15857.1% | -21.5% | -28.3% |
| Valuation | ||||||||
| P/E | — | — | 5.51 | — | — | — | — | — |
| EV/EBITDA | — | — | 10.13 | 12.36 | 49.57 | — | — | — |
| P/B | — | — | 7.21 | — | — | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 20.2% | 20.2% | 20.2% | 6.8% | 6.0% | — | 8.0% | — |
| EPS Growth | 1850.0% | 1850.0% | — | 91.5% | 80.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-17.4%
EPS terminal req.
$0.59
Spread vs growth
1867.4%
5Y implied EPS CAGR
-7.4%
EPS terminal req.
$0.72
Spread vs growth
1857.4%
10Y implied EPS CAGR
0.9%
EPS terminal req.
$1.15
Spread vs growth
1849.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → 1.05
Residual
+25.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.